News
ALGS
0.5399
-0.02%
-0.0001
ALIGOS THERAPEUTICS INC: CLINICAL STUDY IS EXPECTED TO BEGIN AFTER APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION IN CHINA
Reuters · 4d ago
Weekly Report: what happened at ALGS last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at ALGS last week (0708-0712)?
Weekly Report · 07/15 09:17
Aligos Therapeutics To Host Key Opinion Leader Event To Discuss The Phase 1b Data From ALG-000184 For The Treatment Of CHB
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans scheduled for Thursday, July 18, 2024 at 3:00pm ET. Aligos Therapeutics, Inc. Is a clinical stage biopharmaceutical company focused on chronic hepatitis B.
Benzinga · 07/10 12:12
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
NASDAQ · 07/08 15:38
Weekly Report: what happened at ALGS last week (0701-0705)?
Weekly Report · 07/08 09:17
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
NASDAQ · 07/05 14:22
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
NASDAQ · 07/04 13:42
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
NASDAQ · 07/03 13:13
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
NASDAQ · 07/03 13:10
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
NASDAQ · 07/02 16:12
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
NASDAQ · 07/02 15:00
Weekly Report: what happened at ALGS last week (0624-0628)?
Weekly Report · 07/01 09:17
Aligos Therapeutics Shareholders Back Key Corporate Resolutions
TipRanks · 06/28 20:29
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
NASDAQ · 06/27 14:38
Here's Why You May Invest in Theravance (TBPH) Stock Now
NASDAQ · 06/26 15:28
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
NASDAQ · 06/26 15:13
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
NASDAQ · 06/25 15:04
Weekly Report: what happened at ALGS last week (0617-0621)?
Weekly Report · 06/24 09:18
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
NASDAQ · 06/21 12:49
More
Webull provides a variety of real-time ALGS stock news. You can receive the latest news about Aligos Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.